Rocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on Monday

Rocket Pharmaceuticals (NASDAQ:RCKT) is expected to issue its quarterly earnings data before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $0.03 million for the quarter.

Rocket Pharmaceuticals Trading Down 3.7 %

NASDAQ RCKT opened at $10.47 on Friday. The company has a market cap of $954.45 million, a PE ratio of -3.81 and a beta of 0.98. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals has a 12 month low of $9.33 and a 12 month high of $31.47. The stock has a 50 day moving average of $11.10 and a 200-day moving average of $15.05.

Analyst Upgrades and Downgrades

RCKT has been the subject of several recent analyst reports. Wedbush started coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a report on Monday, November 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $47.27.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.